methyl-trans-4-ethylcyclohexanecarboxylate | 75839-91-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl-trans-4-ethylcyclohexanecarboxylate
• 英文别名: trans-methyl 4-ethylcyclohexanecarboxylate
• CAS: 75839-91-7
• 化学式: C₁₀H₁₈O₂
• 分子量: 170.252
• InChiKey: YSEHHONJTYBLJV-KYZUINATSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.38
• 重原子数：
  12.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  26.3
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  methyl-trans-4-ethylcyclohexanecarboxylate 在 mercury dibromide 作用下， 以 环己烷 为溶剂， 生成 cis-methyl 4-ethylcyclohexanecarboxylate
  参考文献：
  名称：

  Matteis, Cristina I. De; Utley, James H. P., Journal of the Chemical Society. Perkin transactions II, 1992, # 6, p. 879 - 883

  摘要：

  DOI：
• 作为产物：
  描述：

  cis-methyl 4-ethylcyclohexanecarboxylate 在 mercury dibromide 作用下， 以 环己烷 为溶剂， 生成 methyl-trans-4-ethylcyclohexanecarboxylate
  参考文献：
  名称：

  Matteis, Cristina I. De; Utley, James H. P., Journal of the Chemical Society. Perkin transactions II, 1992, # 6, p. 879 - 883

  摘要：

  DOI：

文献信息

• 3-Carbamoyl-2-Pyridone Derivative
  申请人：Ishizuka Natsuki

  公开号：US20080103139A1

  公开（公告）日：2008-05-01

  The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I): wherein R 1 is optionally substituted C1-C8 alkyl and the like; R 2 is C1-C6 alkyl; R 3 is C1-C6 alkyl and the like; or R 2 and R 3 taken together with may form an optionally substituted 5 to 10 membered non-aromatic carbon ring; R 4 is hydrogen and the like; G is a group selected from the groups shown by the formula an the like: wherein R 5 is hydrogen and the like; X 1 is a single bond and the like; X 2 is optionally substituted C1-C8 alkylene that may be replaced by one or two groups of —O—, or —N(R 6 )—, wherein R 6 is hydrogen and the like, and the like; X 3 is a single bond and the like; a pharmaceutically acceptable salt or a solvate thereof, and pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially anti-pruritus agents for oral used and for external application, which each contains the said compound as an active ingredient.

  本发明提供了具有激动大麻素受体的作用的化合物，其由式（I）表示：其中，R1是可选取的取代的C1-C8烷基等；R2是C1-C6烷基；R3是C1-C6烷基等；或R2和R3共同形成可选取代的5至10个成员的非芳香碳环；R4是氢等；G是由式等所示的基团中选取的基团：其中，R5是氢等；X1是单键等；X2是可选取代的C1-C8烷基，可以被一或两个-O-或-N（R6）-的基团替代，其中R6是氢等；X3是单键等；其药学上可接受的盐或其溶剂，以及制药组合物、治疗特应性皮炎的制剂和抗瘙痒剂，特别是口服和外用的抗瘙痒剂，每种制剂均以所述化合物为活性成分。
• SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20140296214A1

  公开（公告）日：2014-10-02

  The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.

  本发明提供了公式(I)的化合物或其立体异构体，其药学上可接受的盐，其中所有变量如本文所定义。这些化合物是XIa因子和/或血浆卡利肌酶的抑制剂，可用作药物。
• BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE
  申请人：Boezio Christiane M.

  公开号：US20130217668A1

  公开（公告）日：2013-08-22

  Compounds of Formula (I) are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula (I) have the following structure: where the definitions of the variables are provided herein.

  公式（I）的化合物是阿纳普拉斯腺瘤激酶的有用抑制剂。公式（I）的化合物具有以下结构：其中变量的定义在此提供。
• Intermediates for the preparation of fused bicyclic mTOR inhibitors
  申请人：OSI Pharmaceuticals, Inc.

  公开号：EP2385053A2

  公开（公告）日：2011-11-09

  A compound represented by the formula I or II:

  由式 I 或 II 所代表的化合物：
• Antifibrinolytic compounds
  申请人：THROMBOLYTICS, LLC

  公开号：US10202331B2

  公开（公告）日：2019-02-12

  The present invention provides novel and antifibrinolytic compounds, processes for their preparation, pharmaceutical and veterinary compositions thereof, and their use in medicine, in particular for the treatment of bleeding. The present application relates to numerous embodiments of chemical structures which in whole or in part mimic or are analogs of the amino acid Lysine such that they bind to specific binding site(s) within specific protein sub structures in the structures of Plasminogen, and/or Plasmin, and/or Plasminogen Activators, and/or Thrombin.

  本发明提供了新型抗纤维蛋白溶解化合物、其制备工艺、药物和兽药组合物及其在医学中的用途，特别是用于治疗出血。本申请涉及许多化学结构的实施方案，这些化学结构全部或部分模仿氨基酸赖氨酸或其类似物，从而使它们与特定蛋白质子结构中的特定结合位点结合，这些蛋白质子结构包括血浆蛋白酶原、和/或血浆蛋白、和/或血浆蛋白酶原激活剂、和/或凝血酶。